// App-Quantinova.ai

: FCGR2B B2.4 Haplotype Predicts Increased Risk of Red Blood Cell Alloimmunization in Sickle Cell Disease Patients

Researchers

Presenter

  • Abel Costa Neto

Principal Investigators

  • Flvia Leite Santos

  • Ingrid Helena Ribeiro

  • Valeria Brito Oliveira

  • Marcia Regina Dezan

  • Simone Kashima

  • Dimas Tadeu Covas

  • Alexandre Costa Pereira

  • Guilherme Henrique Hencklain Fonseca

  • Frederico Moreira

  • Jos Eduardo Krieger

  • Sandra Fatima Menosi Gualandro

  • Vanderson Rocha

  • Alfredo Mendrone

  • Carla Luana Dinardo

Medical Centers

  • Serviço de Hematologia, Hemoterapia e Terapia Celular - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo/Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil

  • Regional Blood Center of Ribeirão Preto - Faculty of Medicine of Ribeirão Preto - University of São Paulo, Ribeirão Preto, Brazil

  • Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil

  • Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo, São Paulo, Brazil

  • Department of Hematology, Churchill Hospital, NHS BT, Oxford University, Oxford, United Kingdom

Locations

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

Biomarkers

  • Stearoyl-CoA desaturase

  • Red Blood Cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved